{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T22:40:51Z","timestamp":1685400051019},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.intimp.2010.01.010","type":"journal-article","created":{"date-parts":[[2010,2,2]],"date-time":"2010-02-02T09:57:15Z","timestamp":1265104635000},"page":"487-492","source":"Crossref","is-referenced-by-count":2,"title":["Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide+Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis"],"prefix":"10.1016","volume":"10","author":[{"given":"E.J.","family":"Shannon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2010.01.010_bib1","first-page":"419","article-title":"Advances in the treatment of monoclonal gammopathies: the emerging role of targeted therapy in plasma cell dyscrasias","volume":"2","author":"Roccaro","year":"2008","journal-title":"Biologics"},{"issue":"12","key":"10.1016\/j.intimp.2010.01.010_bib2","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1182\/blood-2008-04-150854","article-title":"Thalidomide and rituximab in Waldenstr\u00f6m macroglobulinemia","volume":"112","author":"Treon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2010.01.010_bib3","first-page":"254","article-title":"A bacterologic study of erythemal nodosum leprosum","volume":"28","author":"Ridley","year":"1960","journal-title":"Int. J. Lepr. Other Mycobacterial Dis."},{"key":"10.1016\/j.intimp.2010.01.010_bib4","first-page":"95","article-title":"The immunopathology of erythema nodosum leprosum: the role of extra-vascular complexes","volume":"54","author":"Ridley","year":"1983","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.intimp.2010.01.010_bib5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(69)90592-3","article-title":"Erythema nodosum leprosum: a clinical manifestation of the Arthus phenomenon","volume":"2","author":"Wemambu","year":"1969","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2010.01.010_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0090-1229(92)90227-F","article-title":"Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum","volume":"63","author":"Scollard","year":"1992","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.intimp.2010.01.010_bib7","series-title":"Skin biopsy of leprosy. Histological interpretation and clinical application","author":"Ridley","year":"1977"},{"key":"10.1016\/j.intimp.2010.01.010_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/IAI.27.2.297-301.1980","article-title":"In vitro synthesis of anti-mycobacterial antibodies in biopsies from skin lesions of leprosy patients","volume":"27","author":"Lai-A-Fat","year":"1980","journal-title":"Infect. Immun."},{"key":"10.1016\/j.intimp.2010.01.010_bib9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders","volume":"121","author":"International Meloma Working Group","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2010.01.010_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60720-8","article-title":"Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system","volume":"32","author":"Waldmann","year":"1982","journal-title":"Adv. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2010.01.010_bib11","first-page":"399","article-title":"Glucocorticosteroid enhancement of immunoglobulin synthesis by pokeweed mitogen-stimulated human lymphocytes. III. Common variable immunodeficiency","volume":"45","author":"Cooper","year":"1981","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2010.01.010_bib12","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4049\/jimmunol.119.2.598","article-title":"Activation of human B lymphocytes. IV. Regulatory effects of corticosteroids on the triggering signal in the plaque-forming cell response of human peripheral blood B lymphocytes to polyclonal activation","volume":"119","author":"Fauci","year":"1977","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2010.01.010_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0162-3109(96)00154-3","article-title":"Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-\u03b1","volume":"36","author":"Shannon","year":"1997","journal-title":"Immunopharmacology"},{"issue":"4","key":"10.1016\/j.intimp.2010.01.010_bib14","first-page":"177","article-title":"Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations","volume":"46","author":"Zwingenberger","year":"1996","journal-title":"J. Inflamm."},{"key":"10.1016\/j.intimp.2010.01.010_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J. of Clin. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2010.01.010_bib16","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/cncr.11072","article-title":"A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications","volume":"97","author":"Lauta","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2010.01.010_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0162-3109(95)00039-7","article-title":"Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative","volume":"31","author":"Shannon","year":"1995","journal-title":"Immunopharmacology"},{"issue":"11","key":"10.1016\/j.intimp.2010.01.010_bib18","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2010.01.010_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/08923970802135161","article-title":"Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide","volume":"30","author":"Shannon","year":"2008","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"3","key":"10.1016\/j.intimp.2010.01.010_bib20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4049\/jimmunol.138.3.795","article-title":"The role of interleukin 2 in inducing Ig production in a pokeweed mitogen-stimulated mononuclear cell system","volume":"138","author":"Nakagawa","year":"1987","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2010.01.010_bib21","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.4049\/jimmunol.133.5.2442","article-title":"Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2","volume":"133","author":"Ralph","year":"1984","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2010.01.010_bib22","first-page":"178","article-title":"Interleuckin-6 in biology and medicine","volume":"54","author":"Akira","year":"1993","journal-title":"Adv. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2010.01.010_bib23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-3083.1981.tb00169.x","article-title":"Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy","volume":"13","author":"Shannon","year":"1981","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2010.01.010_bib24","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0002-9378(15)33755-8","article-title":"Effect of thalidomide on the antibody response","volume":"100","author":"Gusdon","year":"1964","journal-title":"A. J. Obstet. Gynaecol."},{"issue":"5","key":"10.1016\/j.intimp.2010.01.010_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-3083.1994.tb03501.x","article-title":"Immunostimulatory effect of thalidomide in normal C57BL\/6 mice is compatible with stimulation of a highly connected central immune system","volume":"40","author":"Arala-Chaves","year":"1994","journal-title":"Scand. J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2010.01.010_bib26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1472-8206.1988.tb00650.x","article-title":"Enhancement of antibody response and delayed-type hypersensitivity by thalidomide in mice","volume":"2","author":"Descotes","year":"1988","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2010.01.010_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/excr.1996.0027","article-title":"Reversible G1 arrest induced by dimethyl sulfoxide in human lymphoid cell lines: dimethyl sulfoxide inhibits IL-6-induced differentiation of SKW6-CL4 into IgM-secreting plasma cells","volume":"222","author":"Teraoka","year":"1996","journal-title":"Exp. Cell Res."},{"issue":"9","key":"10.1016\/j.intimp.2010.01.010_bib28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.onc.1202040","article-title":"Early G1 growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21[CIP1] induction","volume":"17","author":"Ponzio","year":"1998","journal-title":"Oncogenes"},{"key":"10.1016\/j.intimp.2010.01.010_bib29","unstructured":"Eriksson T, Pharmacokinetics of the enantiomers of thalidomide PhD Thesis. Department of Clinical Pharmacology, Lund University, Lund and Hospital Pharmacy, Malm\u00f6 University Hospital, Sweden, 1997;287:388\u201397."},{"key":"10.1016\/j.intimp.2010.01.010_bib30","first-page":"287","article-title":"Corticosteroids and lymphoid cells","author":"Claman","year":"1972","journal-title":"New Eng. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2010.01.010_bib31","first-page":"97","article-title":"Current views on reactions in leprosy","volume":"72","author":"Naafs","year":"2000","journal-title":"Indian J. Lepr."},{"issue":"3","key":"10.1016\/j.intimp.2010.01.010_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.47276\/lr.79.3.311","article-title":"Activation of complement by Mycobacterium leprae requires disruption of the bacilli","volume":"79","author":"Lahiri","year":"2008","journal-title":"Lepr. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2010.01.010_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/CDLI.12.1.130-134.2005","article-title":"Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages","volume":"12","author":"Tadesse","year":"2005","journal-title":"Clin. and Diag. Lab. Immunol"},{"issue":"5","key":"10.1016\/j.intimp.2010.01.010_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/1523-1747.ep12354963","article-title":"IgM and IgG antibodies to phenolic glycolipid I from Mycobacterium leprae in leprosy: insight into patient monitoring, erythema nodosum leprosum, and bacillary persistence","volume":"86","author":"Levis","year":"1986","journal-title":"J. Invest. Dermatol"},{"issue":"21","key":"10.1016\/j.intimp.2010.01.010_bib35","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2010.01.010_bib36","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00280-009-0987-8","article-title":"Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb\/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn","volume":"64","author":"Israyelyan","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.intimp.2010.01.010_bib37","first-page":"1680","article-title":"Thalidomide metabolites in mice and patients with multiple myeloma","volume":"9","author":"Lu","year":"2003","journal-title":"Clin. Cancer Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576910000330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576910000330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T22:08:02Z","timestamp":1685398082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576910000330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S1567576910000330"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2010.01.010","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}